Insider
Amgen IncAMGN

Amgen reports profit growth amid regulatory challenges

Amgen reported third quarter 2026 quarterly revenue growth of 8.5% to $10.4 billion and net income growth of 20.1% to $3.9 billion. The report also details new regulatory challenges and clinical trial results shaping the operating environment for shareholders.

Verified against 6 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
Abstract shiny fluid shape amidst scattered white cubes
Photo by Brecht Corbeel on Unsplash
$10.4 billion
Quarterly revenue
$3.9 billion
Quarterly net income
8.5%
Revenue growth, y/y

Key points

  • In its third quarter 2026 financial report, the company confirmed the negative impact of Inflation Reduction Act (IRA) provisions and expanded use of the 340B program on its performance.
  • Amgen announced positive Phase 3 results for several products.
  • On November 6, 2026, directors Michael V. Drake, David W. Gibbs, Charles M. Holley, and Omar Ishrak received company shares as compensation.

Financial results and regulatory pressure

In its third quarter 2026 financial report, the company confirmed the negative impact of Inflation Reduction Act (IRA) provisions and expanded use of the 340B program on its performance. CMS selected ENBREL and Otezla for Medicare price setting beginning in 2026 and 2027, respectively. In response, the company will participate in a one-year 340B rebate pilot program starting in January 2027, though it notes this may not fully offset the effects of improper discount utilization.

Quarter vs the same quarter a year earlier

Jul–Sep 2025Jul–Sep 2026Revenue+8.5%$9.6B$10.4BNet income+20.1%$3.2B$3.9B
Data from the original sources listed alongside.

Clinical achievements and safety

Amgen announced positive Phase 3 results for several products. TEZSPIRE demonstrated improvement in patients with eosinophilic esophagitis, Repatha received an expanded indication in Europe to reduce cardiovascular risk, and the DeLLphi-305 study confirmed improved overall survival using IMDELLTRA/IMDYLLTRA.

The company continues to face cybersecurity threats, including incidents affecting third-party service providers. Amgen noted that such cases, including an incident reported in July 2026, can lead to unauthorized data access.

Director transactions

On November 6, 2026, directors Michael V. Drake, David W. Gibbs, Charles M. Holley, and Omar Ishrak received company shares as compensation. The number of shares acquired was: 114.0263 for Drake, 278 for Gibbs, 184.614 for Holley, and 152.0351 for Ishrak.

What to watch

Investors should monitor the final legal status of the Upper Payment Limit (UPL) for ENBREL in Colorado, as its implementation is currently preliminarily enjoined by a court. It is also important to evaluate the effectiveness of the 340B rebate pilot program starting in January 2027 in mitigating financial losses from duplicate discounts.

Original sources

  1. 10-Q risk factors compared with the 10-Q filing, August 5, 2026November 4, 2026SHA-256 of our archived copy 74c08e95bedb…
  2. financial data (XBRL)November 4, 2026SHA-256 of our archived copy 83e90a852fc8…
  3. 4 filing, November 9, 2026November 9, 2026SHA-256 of our archived copy bbd17e6b00e4…
  4. 4 filing, November 9, 2026November 9, 2026SHA-256 of our archived copy ac5c71d43505…
  5. 4 filing, November 9, 2026November 9, 2026SHA-256 of our archived copy 9b92f860fd15…
  6. 4 filing, November 9, 2026November 9, 2026SHA-256 of our archived copy f74da1603203…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards